- Home
- RYTM
as of 02-17-2026 3:46pm EST
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.
| Founded: | 2008 | Country: | N/A |
| Employees: | N/A | City: | BOSTON |
| Market Cap: | 6.4B | IPO Year: | N/A |
| Target Price: | $129.92 | AVG Volume (30 days): | 657.2K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 13 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | N/A | EPS Growth: | N/A |
| 52 Week Low/High: | $45.91 - $122.20 | Next Earning Date: | 01-01-0001 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | 47.98% | Revenue Growth (next year): | 56.07% |
| P/E Ratio: | N/A | Index: | N/A |
| Free Cash Flow: | N/A | FCF Growth: | N/A |
AI-Powered RYTM Daily Prediction
Machine learning model trained on 25+ technical indicators
AI Recommendation
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Rhythm Pharmaceuticals Inc. (RYTM)
Chief Financial Officer
Avg Cost/Share
$98.26
Shares
1,592
Total Value
$156,379.71
Owned After
119,366
Chief Financial Officer
Avg Cost/Share
$99.55
Shares
2,766
Total Value
$272,766.41
Owned After
119,366
Chief Financial Officer
Avg Cost/Share
$103.70
Shares
2,713
Total Value
$279,429.47
Owned After
119,366
Chief Financial Officer
Avg Cost/Share
$106.06
Shares
3,381
Total Value
$358,599.00
Owned After
119,366
SEC Form 4
Chief Financial Officer
Avg Cost/Share
$106.34
Shares
3,247
Total Value
$344,145.15
Owned After
119,366
Chief Human Resources Officer
Avg Cost/Share
$111.00
Shares
3,350
Total Value
$371,850.00
Owned After
20,814
SEC Form 4
Chief Human Resources Officer
Avg Cost/Share
$105.00
Shares
3,350
Total Value
$351,750.00
Owned After
20,814
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Smith Hunter C | RYTM | Chief Financial Officer | Feb 12, 2026 | Sell | $98.26 | 1,592 | $156,379.71 | 119,366 | |
| Smith Hunter C | RYTM | Chief Financial Officer | Feb 11, 2026 | Sell | $99.55 | 2,766 | $272,766.41 | 119,366 | |
| Smith Hunter C | RYTM | Chief Financial Officer | Feb 10, 2026 | Sell | $103.70 | 2,713 | $279,429.47 | 119,366 | |
| Smith Hunter C | RYTM | Chief Financial Officer | Feb 5, 2026 | Sell | $106.06 | 3,381 | $358,599.00 | 119,366 | |
| Smith Hunter C | RYTM | Chief Financial Officer | Feb 4, 2026 | Sell | $106.34 | 3,247 | $344,145.15 | 119,366 | |
| Cramer Pamela J. | RYTM | Chief Human Resources Officer | Dec 11, 2025 | Sell | $111.00 | 3,350 | $371,850.00 | 20,814 | |
| Cramer Pamela J. | RYTM | Chief Human Resources Officer | Nov 20, 2025 | Sell | $105.00 | 3,350 | $351,750.00 | 20,814 |
Compare RYTM vs Leading Stocks
See how RYTM stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "RYTM Rhythm Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.